What is Capture-SELEX? Unlike traditional SELEX where the target is immobilized, Capture-SELEX immobilizes the initial DNA library itself via a short complementary "capture" sequence. The key target molecule is free in solution. Binding occurs when an aptamer candidate in the library binds to the target, causing a structural change that releases it from the immobilization surface. This approach offers distinct advantages: Ideal for small molecules and proteins: Especially targets that are difficult to immobilize without affecting their structure. Minimizes non-specific binding: Selection pressure is purely for target-induced structure formation/release. Enriches for structure-switching aptamers: Resulting aptamers often undergo conformational change upon binding, making them excellent for biosensor development. Typical Capture-SELEX Screening Service Workflow A professional service provider will manage this complex, iterative process from start to finish. Here’s what you can expect: Phase 1: Project Design & Library Preparation Consultation & Target Specification: Defining target properties, desired affinity (Kd), specificity (against which counter-targets), and buffer conditions. Customized Library Design: Designing a single-stranded DNA library (10^14 - 10^15 unique sequences) with: A central random region (e.g., 30-50 nucleotides). Fixed primer regions for PCR amplification. A capture sequence region complementary to an immobilized oligonucleotide. Immobilization Matrix Preparation: Coupling the complementary "capture" oligonucleotides to a solid support (e.g., magnetic beads, chromatography resin). Phase 2: The Iterative Selection (SELEX) Cycles…
What is SELEX and What are Aptamers? Aptamers: Often called "chemical antibodies," they are short, single-stranded DNA or RNA oligonucleotides that fold into specific 3D shapes to bind with high affinity and specificity to a target molecule (e.g., a viral protein, whole bacterium, or parasite surface marker). SELEX (Systematic Evolution of Ligands by EXponential enrichment): This is the iterative combinatorial chemistry process used to discover aptamers from a vast random library (10^14-10^15 unique sequences). It involves repeated cycles of: 1) Binding the library to the target, 2) Separating bound from unbound sequences, 3) Amplifying the bound sequences, and 4) Starting a new, enriched cycle. Core Components of a Pathogen SELEX Service A professional service will typically manage the entire pipeline: 1. Project Design & Target Preparation: Consultation: Defining the precise target (e.g., whole inactivated SARS-CoV-2, Salmonella outer membrane protein, Plasmodium lysate). Counter-SELEX: A critical step for pathogen specificity. The process is run against related non-targets (e.g., host cells, non-pathogenic bacterial strains) to filter out cross-reactive aptamers, ensuring the final aptamers distinguish between pathogen and non-pathogen. 2. The SELEX Execution: Performing multiple (usually 8-15) rounds of the selection process under optimized conditions (buffer, temperature, washing stringency). 3. Next-Generation Sequencing (NGS) & Bioinformatics: After the final rounds, the enriched pool is sequenced using NGS. Bioinformatic analysis identifies sequence…
What is a Bacterial Aptamer Screening Service? It is a specialized contract research service where a provider uses Systematic Evolution of Ligands by Exponential Enrichment (SELEX) to discover and develop single-stranded DNA or RNA aptamers that bind with high affinity and specificity to a bacterial target. The target can be: Whole bacterial cells (e.g., E. coli O157:H7, Salmonella typhimurium). Specific bacterial components (e.g., surface proteins like pili, flagella, capsular polysaccharides, secreted toxins). Key virulence factors (e.g., endotoxins like LPS). The resulting aptamers are powerful recognition elements for diagnostics, therapeutics, and research. Core Steps in the Service Pipeline A typical full-service offering includes: 1. Project Design & Target Preparation: Consultation: Defining the goal (e.g., detection of a specific strain, therapeutic neutralization). Target Choice: Deciding between whole cells (for broad detection) or purified components (for precise targeting). Counter-SELEX: Using related non-target cells (e.g., non-pathogenic strain) to eliminate cross-reactive aptamers and ensure specificity. 2. Library Synthesis & SELEX Process: Library Design: Using a random-sequence oligonucleotide library (typically ~10^14 different molecules). Selection Rounds (8-15 cycles): Iteratively incubating the library with the target, washing away unbound sequences, eluting the bound ones, and amplifying them via PCR (for DNA) or RT-PCR (for RNA). Monitoring: Using quantitative PCR or flow cytometry to track enrichment progress. 3. Next-Generation Sequencing (NGS) & Bioinformatics:…
Core Concept: Aptamers vs. Antibodies Aptamers are often called "chemical antibodies." Their key advantages for cancer targeting include: Small size: Better tissue penetration. In vitro synthesis: Highly reproducible, no batch-to-batch variation. Ease of modification: Can be chemically tagged with dyes, drugs, or nanoparticles. Low immunogenicity. Target Range: Can bind to proteins, carbohydrates, lipids, or even complex molecular patterns on a whole cell's surface. The Screening Service Workflow (Cell-SELEX) A typical service follows these steps: 1. Project Design & Target Selection Client Input: You define the target (e.g., "Aptamers for metastatic triple-negative breast cancer cell line MDA-MB-231"). Counter-Selection: Crucial step. To ensure specificity, the service provider will also use a control cell line (e.g., normal breast epithelial cells or a less aggressive cancer type) to remove aptamers that bind to common, non-target molecules. Library Design: The provider uses a vast random oligonucleotide library (e.g., 10^14 different sequences). 2. The SELEX Process This is an iterative, multi-round biochemical "fishing" experiment: Incubation: The library is exposed to the target cancer cells. Washing: Weakly or unbound sequences are washed away. Elution: Bound aptamers are recovered (e.g., by heating or trypsinizing cells). Amplification: Recovered aptamers are amplified by PCR (for DNA) or RT-PCR (for RNA). Stringency Increase: In each subsequent round, conditions become stricter (more washing, shorter incubation, addition…
What is Whole Cell-SELEX? SELEX (Systematic Evolution of Ligands by EXponential enrichment) is a technique used to develop aptamers—single-stranded DNA or RNA oligonucleotides that bind to a specific target molecule with high affinity and specificity, akin to antibodies. Whole Cell-SELEX is a variant where the target is not a purified protein, but an entire living cell. This is crucial for discovering aptamers against: Native cell-surface proteins in their natural conformation and modification state. Complex membrane protein complexes. Disease-specific cell markers (e.g., on cancer cells, pathogens) without prior knowledge of the specific molecular target. Specific cell types in a heterogeneous mixture (e.g., cancer stem cells within a tumor). A service provider performs this technically demanding and iterative process on behalf of researchers or companies. The Core Process of a Whole Cell-SELEX Service A typical service workflow involves close collaboration with the client: 1. Project Design & Consultation Defining Targets: Client specifies the positive selection cell (e.g., human glioblastoma cells) and the critical negative/counter selection cell (e.g., normal astrocytes or a related cell line). This is key to generating selective aptamers. Library Design: The service provider uses a vast (10^14 - 10^15 sequences) random oligonucleotide library. 2. The SELEX Cycle (Iterative Rounds) This is the core experimental phase performed by the service provider: Incubation: The library is incubated…
What is the Core Service? The service provider uses an iterative, in vitro selection process called SELEX (Systematic Evolution of Ligands by EXponential Enrichment) to screen vast random oligonucleotide libraries (10^14 - 10^15 unique sequences) against your target protein. The output is a set of characterized aptamer sequences that bind to the viral capsid. Standardized Screening Workflow A professional service will manage this entire pipeline: 1. Project Design & Target Preparation: Target Discussion: Defining the specific capsid protein (e.g., HIV-1 CA, HBV core, SARS-CoV-2 N), its form (full-length, domain, assembled capsid/nucleocapsid), and purity. Target Immobilization: The protein is often immobilized on a solid support (beads, plate) to facilitate separation of bound/unbound sequences. Some services offer solution-phase or capillary electrophoresis (CE-SELEX) methods for higher stringency. 2. SELEX Selection Rounds (Cycles 5-15): Incubation: The oligonucleotide library is incubated with the target. Partitioning: Unbound sequences are washed away; bound sequences are retained. Elution: Bound aptamers are eluted (e.g., by heating, denaturing agents). Amplification: Eluted aptamers are amplified by PCR (for DNA) or RT-PCR (for RNA). Purification: The amplified pool is purified for the next selection round. Counter-Selection: To ensure specificity, the pool is often passed through a negative control (e.g., irrelevant protein, cell lysate) to remove non-specific binders. 3. Sequencing & Identification: High-Throughput…
What is an Antibody Aptamer Screening Service? It is a specialized contract research service where a biotechnology company uses SELEX (Systematic Evolution of Ligands by EXponential Enrichment) or advanced variations of it to discover and develop aptamers that bind with high affinity and specificity to a target antibody. Antibody: A large, Y-shaped protein produced by the immune system to identify and neutralize pathogens. Aptamer: A short, single-stranded DNA or RNA oligonucleotide (or a modified derivative) that folds into a specific 3D structure, enabling it to bind to a target molecule with antibody-like specificity. Often called "chemical antibodies." The goal of the service is to provide clients with synthetic, recombinant-like binding molecules as alternatives or complements to traditional monoclonal antibodies. Why Screen for Aptamers Against Antibodies? Aptamers offer distinct advantages, making them attractive for various applications: Anti-Drug Antibody (ADA) Detection: Develop aptamer-based assays to detect and quantify ADAs in clinical trials for biotherapeutics. Diagnostic Tools: Create aptamer sensors (aptasensors) to detect specific antibody biomarkers for diseases (e.g., autoantibodies in autoimmune disorders). Therapeutic Neutralization: Discover aptamers that can bind and neutralize pathological antibodies (e.g., in autoimmune diseases like lupus or myasthenia gravis). Purification & Pull-Down: Use aptamers as ligands in chromatography or in assays to capture and isolate specific antibodies from complex…
What is the Service? It's the process of using SELEX (Systematic Evolution of Ligands by EXponential Enrichment) to identify single-stranded DNA or RNA aptamers that can bind to a target cytokine. The service takes you from target selection to delivering validated aptamer candidates. Standard Workflow (What the Provider Does) Project Scoping & Target Preparation: Target: You specify the cytokine (e.g., TNF-α, IL-6, IFN-γ). The provider may require you to supply the purified, recombinant protein or offer to procure/produce it. Counter-SELEX: A critical step to ensure specificity. The provider will use related proteins (e.g., other cytokines, serum proteins) to eliminate aptamers that bind non-specifically. Library Design & SELEX Cycle: Starts with a vast random oligonucleotide library (10^14 - 10^15 unique sequences). Iterative rounds (8-15+) of: Binding: Incubating the library with the target cytokine. Partitioning: Separating bound from unbound sequences (e.g., via immobilization on beads, filters, or capillary electrophoresis). Amplification: PCR (for DNA) or RT-PCR (for RNA) to enrich the binding sequences. Stringency Increase: Gradually increasing washing rigor and introducing counter-selection to drive selection of high-affinity, specific binders. Next-Generation Sequencing (NGS) & Bioinformatics: After the final rounds, the enriched pool is sequenced using NGS. Bioinformatics tools analyze the data to identify enriched sequence families, consensus motifs, and predict secondary structures.…
What is an Aptamer? An aptamer is a short, single-stranded oligonucleotide (DNA or RNA) that folds into a unique 3D structure, allowing it to bind to a specific target molecule (like a protein) with similar specificity to an antibody. They are often called "chemical antibodies." Why Use a Screening Service Instead of In-House Development? Expertise & Equipment: The screening process (SELEX) requires specialized skills, robotics, and next-generation sequencing (NGS) infrastructure. Time & Cost Efficiency: Outsourcing can be faster and more cost-effective than setting up a new, complex pipeline. Higher Success Rate: Experienced providers have optimized protocols for difficult targets (e.g., membrane proteins, toxic proteins). The Core Process: SELEX The standard method is SELEX (Systematic Evolution of Ligands by EXponential Enrichment). A professional service will offer advanced variants of this process. A Typical Service Workflow: Project Consultation & Design: Target Characterization: Discussion about your protein (purified? membrane-bound? post-translational modifications?). Selection Strategy: Choosing the best SELEX method (e.g., Capillary Electrophoresis-SELEX (CE-SELEX) for very high affinity, Cell-SELEX for cell-surface targets, Toggle-SELEX for cross-species specificity). Counter-Selection: Designing the process to avoid binding to non-target proteins (e.g., carrier proteins, related isoforms). Library Synthesis & Preparation: Creation of a vast random oligonucleotide library (typically 10¹³ - 10¹⁵ unique sequences). The Selection Rounds (Cycles of SELEX): Binding: Incubating the library with the…
What is a Metal Ion-Targeted Aptamer Screening Service? It is a contract research service where a specialized laboratory uses an in vitro selection process (most commonly SELEX - Systematic Evolution of Ligands by EXponential Enrichment) to identify single-stranded DNA or RNA oligonucleotides (aptamers) that bind with high affinity and specificity to a specific metal ion (e.g., Pb²⁺, Hg²⁺, UO₂²⁺, As³⁺, Cd²⁺). Unlike aptamers for proteins, metal ion aptamers often rely on the ion's unique coordination chemistry to induce a specific fold or structural switch in the oligonucleotide. Core Service Workflow (The Screening Process) A typical service provider would follow these steps: Design & Library Synthesis: Creation of a vast random-sequence oligonucleotide library (10¹⁴ - 10¹⁵ different sequences). Target Preparation: The target (e.g., Pb²⁺) is often presented in a specific buffer system that controls charge, pH, and the presence of competing ions to drive selection for the desired specificity. Selection Rounds (SELEX Cycle): Binding: Incubate the library with the target metal ion. Partition: Separate metal-bound sequences from unbound ones. This is the most critical and challenging step for small ions. Techniques include: Immobilization: Cheating the ion to a solid support (beads). Capture-SELEX: Using a complementary strand or an auxiliary molecule. Size-based separation: If binding induces a conformational change (e.g., dimerization). Amplification: PCR (for…
